Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EGFR806-specific CAR T cells |
Synonyms | |
Therapy Description |
EGFR806-specific CAR T cells are autologous T-cells engineered with a lentiviral vector to express a chimeric antigen receptor that targets EGFR present in abnormal conformational states, including EGFRvIII and other activating mutants, which result in enhanced anti-tumor response against EGFR-expressing tumors (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EGFR806-specific CAR T cells | autologous CD4+/CD8+ T cells expressing EGFR806-specific CAR/EGFRt | EGFR Immune Cell Therapy 4 | EGFR806-specific CAR T cells are autologous T-cells engineered with a lentiviral vector to express a chimeric antigen receptor that targets EGFR present in abnormal conformational states, including EGFRvIII and other activating mutants, which result in enhanced anti-tumor response against EGFR-expressing tumors (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03638167 | Phase I | EGFR806-specific CAR T cells | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | Active, not recruiting | USA | 0 |